Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)-Reference-Cited by-同舟云学术

Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)

Published:2023-08 Issue:4 Volume:8 Page:101565
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Lv C.,Wang R.,Li S.,Yan S.,Wang Y.,Chen J.,Wang L.,Liu Y.,Guo Z.,Wang J.,Pei Y.,Yu L.,Wu N.,Lu F.,Gao F.,Chen J.,Liu Y.,Wang X.,Li S.,Han B.,Zhang L.,Ma Y.,Ding L.,Wang Y.,Yuan X.,Yang Y.

Funder

Betta Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG 1104);Xu;J Thorac Oncol,2019

2. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data;Arriagada;Lancet,2010

3. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016

4. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer;Burdett;Cochrane Database Syst Rev,2015

5. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China;BMJ Open;2024-08

2. A narrative review on perioperative systemic therapy in non-small cell lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

3. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges;Journal of Thoracic Oncology;2023-09

4. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials;BMC Cancer;2023-08-01